Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
20–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The subject must be 20 and older years of age.
The subject must have cytologically or histologically confirmed non-squamous NSCLC. Subjects may have a mixed histology but must be predominantly non-squamous to be eligible.
The subject must have advanced or metastatic (Stage IV \[According to American Joint Committee on Cancer (AJCC) staging manual, 7th edition\]) disease that is not amenable to surgical resection or radiation with curative intent.
The subject must have not received prior chemotherapy for NSCLC.
The subject has measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
The subject has an Easter Cooperative Oncology Group (ECOG) Performance Score of 0-1.
The subject must have adequate bone marrow, renal and hepatic function.
You may not be if
The subject has hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).
The subject has received any anti-cancer therapy for treatment of NSCLC including investigational agents, immunotherapy, traditional Chinese medicine/herbal remedies, hormonal, "targeted" agents (i.e., erlotinib, imatinib), biologic therapy or cytotoxic chemotherapy (i.e., alkylating agents, microtubule inhibitors, antimetabolites).
The subject has a history of another active cancer within the past 5 years except cervical cancer in situ, in situ carcinoma of the bladder, squamous cell or basal cell carcinoma of the skin.
The subject has active ulcerative colitis, Crohn's disease, celiac disease or any other conditions that interfere with absorption.
The subject has a medical condition, which in the opinion of the study investigator places them at an unacceptably high risk for toxicities.
The subject is pregnant or breast feeding.
The subject has NSCLC with a predominant squamous cell histology.
Clareo Health | A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)
